ReviewPerspectives on behavior science2025
Unpredictable Drug Access and its Relevance for Substance Use Disorders: A Critical Review.
Review in Perspectives on behavior science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many factors contribute to drug use and the development of substance use disorders (SUDs). We and others have argued that individuals who misuse illicit drugs face circumstances in which their access to drugs is variable or unpredictable, particularly for those who are experiencing poverty. Herein, we make the case that such unpredictable drug access increases drug intake and choice, particularly when the time and effort required to obtain drugs is relatively large. If translated to real-world scenarios, unpredictable access could lead to increased severity of drug misuse, poorer treatment outcomes, persistence of drug seeking during periods of drug unavailability, drug taking despite negative consequences, and increased relapse rates, though additional research is surely needed. We describe how variable drug access can be evaluated in the laboratory, review prior research that has compared variable vs. fixed drug access, provide a summary of preclinical findings based on the literature reviewed, and end with implications for policy and treatment for individuals with SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.